Literature DB >> 10533982

Chemotactic effect of urokinase plasminogen activator: a major role for mechanisms independent of its proteolytic or growth factor domains.

A A Poliakov1, S A Mukhina, D O Traktouev, R S Bibilashvily, Y G Gursky, M M Minashkin, V V Stepanova, V A Tkachuk.   

Abstract

Urokinase type plasminogen activator (uPA) converts plasminogen to plasmin and is highly chemotactic for many cell types. We examined, using recombinant wild type and mutated forms of uPA, the extent to which its proteolytic properties, its growth-like domain (GFD) and/or interactions with the specific receptor (uPAR) contribute to the chemotactic activity towards vascular smooth muscle cells (SMC). Recombinant wild type uPA (r-uPA) stimulated cell migration nearly 5.8-fold, inactive r-uPA, with a mutation in the catalitic domain (r-uPA(H/Q)), 3-fold, uPA without growth factor like domain (r-uPA(GFD )), 2.6-fold, and a form containing both mutations (r-uPA(H/Q, GFD ), 3.3-fold. All recombinant forms of uPA, wild type and those with mutations were equally and highly effective (IC50 approximately 20 nM) in displacing 125I-r-uPA bound to SMC. These results indicate that additional mechanisms, not dependent on uPA's proteolytic activity or the binding ability of its GFD to uPAR, are the major contributors to its chemotactic action on SMC.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10533982     DOI: 10.3109/10799899909038433

Source DB:  PubMed          Journal:  J Recept Signal Transduct Res        ISSN: 1079-9893            Impact factor:   2.092


  6 in total

1.  Plasmin-dependent elimination of the growth-factor-like domain in urokinase causes its rapid cellular uptake and degradation.

Authors:  A Poliakov; V Tkachuk; T Ovchinnikova; N Potapenko; S Bagryantsev; V Stepanova
Journal:  Biochem J       Date:  2001-05-01       Impact factor: 3.857

2.  Remodeling of the vessel wall after copper-induced injury is highly attenuated in mice with a total deficiency of plasminogen activator inhibitor-1.

Authors:  V A Ploplis; I Cornelissen; M J Sandoval-Cooper; L Weeks; F A Noria; F J Castellino
Journal:  Am J Pathol       Date:  2001-01       Impact factor: 4.307

3.  A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin.

Authors:  K Mishima; A P Mazar; A Gown; M Skelly; X D Ji; X D Wang; T R Jones; W K Cavenee; H J Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

4.  A novel signaling pathway: fibroblast nicotinic receptor alpha1 binds urokinase and promotes renal fibrosis.

Authors:  Guoqiang Zhang; Kelly A Kernan; Alison Thomas; Sarah Collins; Yumei Song; Ling Li; Weizhong Zhu; Renee C Leboeuf; Allison A Eddy
Journal:  J Biol Chem       Date:  2009-08-18       Impact factor: 5.157

Review 5.  Urokinase and its receptors in chronic kidney disease.

Authors:  Guoqiang Zhang; Allison A Eddy
Journal:  Front Biosci       Date:  2008-05-01

6.  Urokinase upregulates matrix metalloproteinase-9 expression in THP-1 monocytes via gene transcription and protein synthesis.

Authors:  Mikhail Menshikov; Eugenia Elizarova; Karina Plakida; Angelika Timofeeva; Georgy Khaspekov; Robert Beabealashvilli; Alex Bobik; Vsevolod Tkachuk
Journal:  Biochem J       Date:  2002-11-01       Impact factor: 3.857

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.